Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(106)
•••
Post by rodrabalon Feb 09, 2023 1:33pm
715 Views
Post# 35277650

Hope Tlt does the same when there data is released next week

Hope Tlt does the same when there data is released next week
Frequency: 10M
End of interactive chart.

Fundamentals Snapshot (NDAQ:EIGR)

Last
2.765
$ Chg
0.725
Open
2.14
High
2.98
Bid
2.76
Bid Size
1000
Beta
1.92032
Year High
10.021
Market Cap
121.87m
PB Ratio
1.553
EPS
-2.41
Volume
6.35m
% Chg
35.54%
Prev. Close
2.04
Low
2.1089
Ask
2.77
Ask Size
3100
VWAP
2.69693
Year Low
0.96
Total Shares
44.07m
Shares Out
44.07m
Exchange
NSD

Current News (NDAQ:EIGR)

New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19

PR Newswire 20 hours ago

FINAL DEADLINE ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

PR Newswire January 9, 2023

Deadline Alert: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Notifies Eiger BioPharmaceuticals, Inc. (EIGR) Investors of Class Action and Encourages Investors to Actively Participate

Business Wire January 9, 2023

DEADLINE TODAY: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 9, 2023

CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Eiger Investors of a Lead Plaintiff Deadline of January 9, 2023

PR Newswire January 9, 2023

EIGER DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Eiger Biopharmaceuticals, Inc. and Encourages Investors to Contact the Firm

Business Wire January 6, 2023

EIGR FINAL DEADLINE NOTICE: ROSEN, A LEADING NATIONAL FIRM, Encourages Eiger BioPharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important January 9 Deadline in Securities Class Action - EIGR

Newsfile January 6, 2023

Eiger Class Action: Levi & Korsinsky Reminds Eiger BioPharmaceuticals, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 9, 2023 - EIGR

Newsfile January 6, 2023

DEADLINE MONDAY ALERT: The Schall Law Firm Encourages Investors in Eiger BioPharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm

Newsfile January 6, 2023
View More News ››

Opinion & Analysis (NDAQ:EIGR)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:EIGR)

This is when you buy

@$5.15 ...
dragonfly454 - January 3, 2022

RE:200 Day Moving Average is 0.13 Cents Away!

Current high price on July 16, 2017 was 10.25 p/s while the 200 day moving average is 10.38 p/s. That is price difference of 0.13 cents...
stockflower - July 14, 2017

200 Day Moving Average is 0.13 Cents Away!

We are 0.13 cents away from the 200 day moving average! At that point everyone should be confident that share prices will be increasing...
stockflower - July 14, 2017

a

August 31 Deadline in Lawsuit for Investors in Celladon Corp (NASDAQ:CLDN) Shares Announced by Shareholders Foundation 25 Aug 2015...
Trader24 - September 3, 2015

a h

 
Trader24 - September 3, 2015
View more Bullboard ››

 

Good natured Products Inc

Good natured Products Inc

Good Natured Products Inc is engaged in the design, production, and distribution of high-performance bioplastics for use in ... 
View More »

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities